Elisabetta Patorno1, Brian T Bateman2, Krista F Huybrechts2, Sarah C MacDonald2, Jacqueline M Cohen2, Rishi J Desai2, Alice Panchaud2, Helen Mogun2, Page B Pennell2, Sonia Hernandez-Diaz2. 1. From the Division of Pharmacoepidemiology and Pharmacoeconomics (E.P., B.T.B., K.F.H., R.J.D., H.M.), Department of Medicine, and Division of Women's Health and Division of Epilepsy (P.B.P.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School; Department of Anesthesiology, Critical Care, and Pain Medicine (B.T.B.), Massachusetts General Hospital and Harvard Medical School; and Department of Epidemiology (S.C.M., J.M.C., A.P., S.H.-D.), Harvard T.H. Chan School of Public Health, Boston, MA. epatorno@bwh.harvard.edu. 2. From the Division of Pharmacoepidemiology and Pharmacoeconomics (E.P., B.T.B., K.F.H., R.J.D., H.M.), Department of Medicine, and Division of Women's Health and Division of Epilepsy (P.B.P.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School; Department of Anesthesiology, Critical Care, and Pain Medicine (B.T.B.), Massachusetts General Hospital and Harvard Medical School; and Department of Epidemiology (S.C.M., J.M.C., A.P., S.H.-D.), Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
OBJECTIVE: To assess whether first-trimester exposure to pregabalin is associated with an increased risk of major congenital malformations, as recently suggested in a pregnancy registry study. METHODS: We performed a cohort study nested in the US Medicaid Analytic eXtract (MAX). The study population included 1,323,432 pregnancies resulting in a live-born infant between 2000 and 2010. We examined the risk of major congenital malformations among infants born to women exposed to pregabalin during the first trimester compared with women unexposed to anticonvulsants. We used propensity score fine stratification to control for >50 potential confounders, and we estimated relative risks (RRs) and 95% confidence intervals (CIs) in generalized linear models. The analyses were replicated in the Truven Health MarketScan Commercial Database (MarketScan). Pooled estimates based on the adjusted RR produced in MAX, MarketScan, and the previous registry study were calculated. RESULTS: Of 477 infants exposed to pregabalin during the first trimester in MAX, 28 (5.9%) had malformations compared to 3.3% in nonexposed infants. The crude RR of major congenital malformations for pregabalin was 1.80 (95% CI 1.26-2.58). After propensity score adjustment, the RR moved to 1.16 (95% CI 0.81-1.67). Restriction to pregabalin monotherapy and sensitivity analyses produced similar results. The adjusted RR for major congenital malformations for the 174 infants exposed in MarketScan was 1.03 (95% CI 0.56-1.90). The pooled RR was 1.33 (95% CI 0.83-2.15) for pregabalin any use and 1.02 (95% CI 0.69-1.51) for pregabalin monotherapy. CONCLUSIONS: Findings did not confirm the suggested teratogenic effects of pregabalin, although they cannot rule out the possibility of a small effect.
OBJECTIVE: To assess whether first-trimester exposure to pregabalin is associated with an increased risk of major congenital malformations, as recently suggested in a pregnancy registry study. METHODS: We performed a cohort study nested in the US Medicaid Analytic eXtract (MAX). The study population included 1,323,432 pregnancies resulting in a live-born infant between 2000 and 2010. We examined the risk of major congenital malformations among infants born to women exposed to pregabalin during the first trimester compared with women unexposed to anticonvulsants. We used propensity score fine stratification to control for >50 potential confounders, and we estimated relative risks (RRs) and 95% confidence intervals (CIs) in generalized linear models. The analyses were replicated in the Truven Health MarketScan Commercial Database (MarketScan). Pooled estimates based on the adjusted RR produced in MAX, MarketScan, and the previous registry study were calculated. RESULTS: Of 477 infants exposed to pregabalin during the first trimester in MAX, 28 (5.9%) had malformations compared to 3.3% in nonexposed infants. The crude RR of major congenital malformations for pregabalin was 1.80 (95% CI 1.26-2.58). After propensity score adjustment, the RR moved to 1.16 (95% CI 0.81-1.67). Restriction to pregabalin monotherapy and sensitivity analyses produced similar results. The adjusted RR for major congenital malformations for the 174 infants exposed in MarketScan was 1.03 (95% CI 0.56-1.90). The pooled RR was 1.33 (95% CI 0.83-2.15) for pregabalin any use and 1.02 (95% CI 0.69-1.51) for pregabalin monotherapy. CONCLUSIONS: Findings did not confirm the suggested teratogenic effects of pregabalin, although they cannot rule out the possibility of a small effect.
Authors: Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Anne Sabers; Emilio Perucca; Frank Vajda Journal: Lancet Neurol Date: 2011-06-05 Impact factor: 44.182
Authors: Andrea V Margulis; Soko Setoguchi; Murray A Mittleman; Robert J Glynn; Colin R Dormuth; Sonia Hernández-Díaz Journal: Pharmacoepidemiol Drug Saf Date: 2012-05-02 Impact factor: 2.890
Authors: Krista F Huybrechts; Sonia Hernández-Díaz; Elisabetta Patorno; Rishi J Desai; Helen Mogun; Sara Z Dejene; Jacqueline M Cohen; Alice Panchaud; Lee Cohen; Brian T Bateman Journal: JAMA Psychiatry Date: 2016-09-01 Impact factor: 21.596
Authors: Kristin Palmsten; Krista F Huybrechts; Helen Mogun; Mary K Kowal; Paige L Williams; Karin B Michels; Soko Setoguchi; Sonia Hernández-Díaz Journal: PLoS One Date: 2013-06-26 Impact factor: 3.240
Authors: Walaa F Alsanie; Majid Alhomrani; Ahmed Gaber; Hamza Habeeballah; Heba A Alkhatabi; Raed I Felimban; Sherin Abdelrahman; Charlotte A E Hauser; Adeel G Chaudhary; Abdulhakeem S Alamri; Bassem M Raafat; Abdulwahab Alamri; Sirajudheen Anwar; Khaled A Alswat; Yusuf S Althobaiti; Yousif A Asiri Journal: Cells Date: 2022-03-01 Impact factor: 6.600
Authors: Daina B Esposito; Krista F Huybrechts; Martha M Werler; Loreen Straub; Sonia Hernández-Díaz; Helen Mogun; Brian T Bateman Journal: JAMA Netw Open Date: 2022-08-01
Authors: Daina B Esposito; Brian Bateman; Martha Werler; Loreen Straub; Helen Mogun; Sonia Hernandez-Diaz; Krista Huybrechts Journal: Am J Epidemiol Date: 2022-03-24 Impact factor: 5.363
Authors: Andrea V Margulis; Sonia Hernandez-Diaz; Thomas McElrath; Kenneth J Rothman; Estel Plana; Catarina Almqvist; Brian M D'Onofrio; Anna Sara Oberg Journal: PLoS One Date: 2019-08-05 Impact factor: 3.240